Data Year:

For its 2025 fiscal year, QUIDELORTHO CORP, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Michelle A. Hodges
Former CLO
Total Compensation $3,508,070 View details Pay Rank By Title In Biotechnology industry #11 View more
Joseph M. Busky
CFO
Total Compensation $5,355,620 View details Pay Rank By Title In Biotechnology industry #49 View more
Philip D. McLellan
COO
Total Compensation $2,021,992 View details Pay Rank By Title In Biotechnology industry #88 View more
Jonathan P. Siegrist
EVP of R&D and CTO
Total Compensation $1,611,171 View details Pay Rank By Title In Biotechnology industry #14 View more
Brian J. Blaser
President and CEO
Total Compensation $11,255,782 View details Pay Rank By Title In Biotechnology industry #91 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at QUIDELORTHO CORP as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. QUIDELORTHO CORP income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. QUIDELORTHO CORP annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Michelle A. Hodges
Former CLO
Total Cash $1,795,275 Equity $1,697,228 Other $15,567 $3,508,070
Joseph M. Busky
CFO
Total Cash $2,626,327 Equity $2,714,831 Other $14,462 $5,355,620
Philip D. McLellan
COO
Total Cash $1,008,821 Equity $999,240 Other $13,931 $2,021,992
Jonathan P. Siegrist
EVP of R&D and CTO
Total Cash $1,027,640 Equity $569,698 Other $13,833 $1,611,171
Brian J. Blaser
President and CEO
Total Cash $2,274,500 Equity $8,965,822 Other $15,460 $11,255,782
For its 2025 fiscal year, QUIDELORTHO CORP, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Brian J. Blaser CEO Pay $11,255,782 Median Employee Pay $73,316 CEO Pay Ratio 154:1
For its 2024 fiscal year, QUIDELORTHO CORP, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Ann D. Rhoads Total Cash $318,718
Edward L. Michael Total Cash $332,249
Evelyn S. Dilsaver Total Cash $283,750
James R. Prutow Total Cash $285,828
John R. Chiminski Total Cash $96,393
Joseph D. Wilkins, Jr. Total Cash $283,750
Kenneth F. Buechler, Ph.D. Total Cash $421,959
Kenneth J. Widder, M.D. Total Cash $325,716
Mary Lake Polan, M.D., Ph.D., M.P.H. Total Cash $306,243
Matthew W. Strobeck, Ph.D. Total Cash $283,750
R. Scott Huennekens Total Cash $96,393
Robert R. Schmidt Total Cash $43,334
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.